Passa al contenuto
Merck
  • Noradrenergic modulation of masseter muscle activity during natural rapid eye movement sleep requires glutamatergic signalling at the trigeminal motor nucleus.

Noradrenergic modulation of masseter muscle activity during natural rapid eye movement sleep requires glutamatergic signalling at the trigeminal motor nucleus.

The Journal of physiology (2014-05-27)
Peter B Schwarz, Saba Mir, John H Peever
ABSTRACT

Noradrenergic neurotransmission in the brainstem is closely coupled to changes in muscle activity across the sleep-wake cycle, and noradrenaline is considered to be a key excitatory neuromodulator that reinforces the arousal-related stimulus on motoneurons to drive movement. However, it is unknown if α-1 noradrenoceptor activation increases motoneuron responsiveness to excitatory glutamate (AMPA) receptor-mediated inputs during natural behaviour. We studied the effects of noradrenaline on AMPA receptor-mediated motor activity at the motoneuron level in freely behaving rats, particularly during rapid eye movement (REM) sleep, a period during which both AMPA receptor-triggered muscle twitches and periods of muscle quiescence in which AMPA drive is silent are exhibited. Male rats were subjected to electromyography and electroencephalography recording to monitor sleep and waking behaviour. The implantation of a cannula into the trigeminal motor nucleus of the brainstem allowed us to perfuse noradrenergic and glutamatergic drugs by reverse microdialysis, and thus to use masseter muscle activity as an index of motoneuronal output. We found that endogenous excitation of both α-1 noradrenoceptor and AMPA receptors during waking are coupled to motor activity; however, REM sleep exhibits an absence of endogenous α-1 noradrenoceptor activity. Importantly, exogenous α-1 noradrenoceptor stimulation cannot reverse the muscle twitch suppression induced by AMPA receptor blockade and nor can it elevate muscle activity during quiet REM, a phase when endogenous AMPA receptor activity is subthreshold. We conclude that the presence of an endogenous glutamatergic drive is necessary for noradrenaline to trigger muscle activity at the level of the motoneuron in an animal behaving naturally.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Fosfato di potassio, ACS reagent, ≥99.0%
Sigma-Aldrich
Saccarosio, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Saccarosio, ≥99.5% (GC)
Sigma-Aldrich
Sodio cloruro, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Saccarosio, ≥99.5% (GC), BioXtra
Sigma-Aldrich
Sodio cloruro, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Fosfato di potassio, powder, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Sodio cloruro, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Sodio cloruro, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Saccarosio, BioUltra, for molecular biology, ≥99.5% (HPLC)
Sigma-Aldrich
Sodio cloruro, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Supelco
Saccarosio, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Saccarosio, United States Pharmacopeia (USP) Reference Standard
SAFC
Sodio cloruro, 5 M
Sigma-Aldrich
Saccarosio, ≥99.5% (GC), BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Saccarosio, ≥99.5% (GC)
Sigma-Aldrich
Fosfato di potassio, for molecular biology, ≥98.0%
Sigma-Aldrich
Sodio cloruro, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
Fosfato di potassio, ReagentPlus®